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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S7decreases not only due to chemotherapy-induced neutropenia, but also
due to the reduction of serum antibody titers gained from previous
immunizations.Children are at an high risk for developing hepatitis B virus
(HBV) infection from immunosuppression secondary to chemotherapy and
multiple blood transfusions. Most of the children infected with HBV
develop chronic hepatitis. An Indian study by Jacob Puliyel et al, showed at
6 years of age, protective levels of anti-HBs antibody (>10 mlU/mL) were
present only in about 59% of those immunized. By 11 years, only 13% had
protective levels. The increasing potential for the cure of childhood ALL
emphasizes the need for a method of reducing hepatitis and its sequelae in
these children. Our study revealed only 68.8% children with newly diag-
nosed ALL had protective antiHBstitres (>10IU/L), while 31.2% children had
no immunity tohepatitis B despite presumed vaccination as part of the UIP
schedule.
Conclusion: A signiﬁcant number of newly diagnosed children with ALL
lack protective anti HBs titres despite being vaccinated according to Uni-
versal Immunization Programme and Combined passive active immuni-
sation should be considered for them.
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Introduction: ETPALL is a recently well described high-risk subset of T-ALL
with early differentiation arrest and showing features overlappingwith AML
andwith poor prognosis which can potentially be improvedwith intensiﬁed
induction using dexamethasone and high-dose L-asparaginase. We audited
our experience with ETP-ALL for its clinical proﬁle and outcome.
Methods: We retrospectively evaluated all children (<15yrs) diagnosed
with ETP-ALL or Near ETP-ALL from January 2012 to December 2015. All
were treated with institutional ALL protocol (modiﬁed MCP-841) with
4drug induction incorporating prednisolone and high dose Ara-C in
consolidation (16g/m2). From June 2014, the protocol was amended by
substituting prednisolone with dexamethasone (10mg/m2/dy) in induc-
tion along with higher intensity of L-asparaginase (10000 U/m2/dose).
Results: T-ALL was diagnosed in 283 children, of whom 34 were ETP-ALL
(14%) and 5 were Near ETP-ALL (1.7%): Median age was -13 years; Male : fe-
male- 2.5:1; Bulky disease-18%; mediastinal mass-12.8%; median WBC
count- 10.1x109/mm3; Hyperleucocytosis (>100x109mm3)- 10%; No CNS
involvement.DemographicsofT-ALL insameperiod:medianage-9yrs;male:
Female 4:1; medianWBC count- 50x109 /mm3; hyperleucocytosis-36.7%.
Of 39 childrenwith ETP-ALL, 32 took treatment. At a median follow-up of 10
months (range3 -50months), the2-yearOS is52.5%andEFS is53.7%.Median
OS is not reached as yet. Of 32 patients, 15 received prednisolone based in-
duction and17 received dexamethasonebased intensive induction. Overall 8
(25%) died during induction therapy (dexamethasone arm e 29.4%, pred-
nisolone arm -20%). Of the evaluable 24 patients (dexamethasone arm-12,
prednisolone arm-12),18 patients (75%) achieved complete morphological
remission at the end of induction (dexamethasone arm-58%, prednisolone
arm-92%, p¼0.15). Of 14 patients whose Minimal Residual Disease (MRD)
datawere available (12 of whom received dexamethasone based induction),
5 patients were MRD negative post induction (35.7%), and corresponding
morphological remission was seen in 9 (50%). Of the 9 patients who were
MRD positive post induction,7 (78%) cleared MRD post subsequent cycles
.There has been no relapse so far and the projected 2-year DFS is 89%.
Conclusions: ETP-ALL constituted 16% of T-ALL children. Children with
ETP-ALL had higher median age, low disease burden at presentation and
infrequent CNS involvement. The disease free survival with this protocol
using high dose cytarabine based consolidation is good. However inten-
siﬁcation of therapy in induction did not improve remission rates but led to
higher induction mortality and poorer overall outcome in our low-middle
income setting.LM-1_V1.4
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Introduction: Acute lymphoblastic leukemia (ALL) is a hematologic ma-
lignancy that predominantly occurs in children between 2 and 10 years of
age. L-asparaginase is an integral component of treatment for patients
with ALL and since its introduction into pediatric treatment protocols in
the 1960s, survival rates in children have progressively risen to nearly 90%.
The effects of L-asparaginase on hemostasis during induction chemo-
therapy are less deﬁned in children. These hemostatic modiﬁcations
induced by L-asparaginase are relatively rare and mild in children, but
their incidence has not yet beenwell evaluated and their Toxicity proﬁle in
Indian children is very rarely documented.
Aims and Objectives: Primary Objective: To demonstrate the toxicity
proﬁle of L- Asparaginase in childrenwith Acute Lymphoblastic Leukaemia
speciﬁcally to evaluate hyperlipidemia and changes in coagulation and
thrombotic risk.
Secondary Objective: To study the differences in toxicities of L-Aspar-
aginase between the two types of L-Asparaginase (E coli and Pegylated).
Methodology:
 Children after the diagnosis with acute lymphoblastic leukemia under-
went baseline investigations with Liver function tests, Lipase, PT, PTT, INR,
Random blood sugar and Lipid proﬁle prior to the onset of treatment and
thereafter weekly during induction and re induction periods.
 Antithrombin III and ﬁbrinogen were done twice during induction (day
15 and 29) and once during reinduction therapy (on day 22).
 Demographic data, clinical details, details of diagnosis, Laboratory values
were recorded in a proforma. Analyzed data were analysed using SPSS 16.
The study was approved by our institution ethics committee.
 The study was funded by Tiara Hemophilia Cancer Foundation, NGO
supporting in Chennai supports pediatric cancer researches.
Results: 80 cases were included in this study of which 53 were males and
27 were females. Pre B cell leukemia were 57 and T cell Leukemia were 23.
Type of L- Asparagine used were E coli Asparaginase (n-50) and Pegylated
L Asparaginase (n-30). Complications seen were elevated lipase level
without any evidence of clinical pancreatitis 12.5%, Hyperglycemia 12.5%,
hyperlipidemia 10%, Thrombosis 2.5%, Allergies 5.6%, elevated PT/PTT 10%;
Low AT 3 (15.5%) and low ﬁbrinogen (16.5%).
There is no Statistical difference between the two groups of L-Asparginase
studied, however increase side effects were noted in Ecoli Asparaginase
group.
Conclusion:
 Asparaginase is a critical component of all pediatric ALL protocols, with
many protocols incorporating prolonged and high intensity L-Aspar-
aginase treatment, it is important that our Indian data be available of all
potential treatment-related toxicities.
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Introduction: Hyperglycemia occurs in about 10-16% of children during
induction chemotherapy for acute lymphoblastic leukemia (ALL), which
includes steroids and L asparaginase. Patients may present with diabetic
ketoacidosis or non-ketotic hyperglycemic hyperosmolar syndrome. Hy-
perglycemia has also been reported to suppress immune function by in-
hibition of endogenous production of interleukins 2, 6 and 10 and
uncontrolled diabetes is a risk factor for developing invasive fungal
infections.
Materials and Methods: This study analysed the incidence and outcome
of hyperglycemia in pediatric patients (0-14yrs) during induction
